Antelope Tx was created by Antibody-drug conjugates (ADC) experts (former co-founder/CSO & CBO of Mablink bioscience, acquired by Eli Lilly in 2023) to develop a novel platform of ADC.

The first drug candidate in its pipeline is addressing gastro-intestinal (GI) cancers and especially colorectal cancers (CRC). The first-in-human trial is planned for H1 2027.

The lead asset (ATL-024) is targeting a first-in-class target, with a novel topo1i drug-linker. It has reached the "drug candidate" status, with NHP preliminary toxicology data and target-specific PDX & CDX efficacy data on CRC models. It is now available for partnering.

We are interested in meeting with ambitious biotech and pharma companies that will develop ATL-024 in the clinic to demonstrate its potential to help CRC and other GI cancer patients.

To continue our corporate development, we will also meet with investors interested to have a stake in the GI cancer landscape.

WE WILL NOT MEET WITH CDMOs, CROs, etc.